|
|
|
|
| Adeno-associated virus (AAV) is a prominent vector for gene delivery to treat life-threatening genetic diseases. A limitation for product development and treatment availability is the need for high levels of infectious AAV particles. We'll show that feeding cell cultures post-transfection (HEK293 cells) or post-infection (insect cells) can boost AAV titers. Data will be shared on the optimization of using Cellvento® ModiFeed Prime COMP to boost AAV titers. Register. |
|
|
|
|
By Alex Klarer, Founder, Managing Director, Engelex | This article explores how the disparity between the number of CDMOs and CGT clinical trials came about and how the market for manufacturing services will change as a result. |
|
|
| Optimizing CGT Development With Modular, Semi-Automated Approaches | Article | By Rubina Pal and Alicia Kramer, Comprehensive Cell Solutions, A Business Unit of NYBC Enterprises | There are a number of technology solutions that, when applied to a cell and gene therapy workflow, can streamline development and improve workflow integration. |
|
|
| Overcoming Challenges In AAV And LV Viral Vector Manufacturing | White Paper | By Mathias Kahl, Stephan Bauer, Dr. Daniel Köhler, et al., IDT Biologika | Manufacturing viral vectors leaves sponsors vulnerable to high costs, delays, and the possibility of failure. The right CDMO partner can help you reduce timelines and costs for viral vector production. |
|
|
|
|
| Considerations For Functional Viral Vector Titration By Flow Chemistry | White Paper | By John Nguyen, Joshua Gutierrez, Venkatesh Natarajan, Ph.D., and Frank Luh, Theragent | Accurately quantifying viral titers is a challenge in the manufacturing of viral vectors. Gain valuable insights into improving the robustness and reproducibility of viral vector functional titers. |
|
|
| Delivering The Promise Of Gene Therapy | Article | Battelle | Gene therapies rely on efficient, precise methods of delivering genetic material. Examine how combining polymeric nanoparticles with CRISPR therapies is increasing the potential for improved treatment. |
|
|
| Cell Line Development For AAV | Q&A | AGC Biologics | As advanced therapies race forward, staying ahead is paramount. By harnessing the right technology, sponsors can unlock efficiencies and propel AAV production to new heights. |
|
|
| Potent Immune Response With Vernal's LNP-mRNAs | Article | By Julia Sakamoto, Vernal Biosciences | Understand how trusted manufacturing partners will continue to play a pivotal role in translating innovative concepts into clinical reality as mRNA medicine continues to evolve. |
|
|
|
|
|
|
|
|
|
|
|
| Connect With Cell & Gene: |
|
|
|
